| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abnormal microvasculature in chronic viral hepatitis
|
Sarcognato, S.
|
|
2017
|
49 |
1S |
p. e10-
1 p.
|
artikel
|
| 2 |
Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR
|
Caviglia, G.P.
|
|
2017
|
49 |
1S |
p. e36-
1 p.
|
artikel
|
| 3 |
Advanced BCLC hepatocellular carcinoma includes a very heterogeneous patient population treatable with different therapies and with different prognosis
|
Garuti, F.
|
|
2017
|
49 |
1S |
p. e43-
1 p.
|
artikel
|
| 4 |
A genic and epigenetic combination therapy for liver cancer
|
Rinaldi, L.
|
|
2017
|
49 |
1S |
p. e43-e44
nvt p.
|
artikel
|
| 5 |
A.I.S.F.
|
|
|
2017
|
49 |
1S |
p. e71-
1 p.
|
artikel
|
| 6 |
An elevated degree of genetic variability characterizes Hepatitis Delta Antigen (HDAg) and correlates with high levels of serum HDV-RNA: Implication for disease progression and design of new pharmacological targets
|
Colagrossi, L.
|
|
2017
|
49 |
1S |
p. e40-
1 p.
|
artikel
|
| 7 |
A new strategy to improve the liver engraftment efficiency of transplanted human biliary tree stem/progenitor cells (hBTSCs): Cell coating with hyaluronic acid
|
Nevi, L.
|
|
2017
|
49 |
1S |
p. e11-
1 p.
|
artikel
|
| 8 |
Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib
|
Marisi, G.
|
|
2017
|
49 |
1S |
p. e19-
1 p.
|
artikel
|
| 9 |
A novel role for heparanase in the onset of liver fibrosis
|
Secchi, M.F.
|
|
2017
|
49 |
1S |
p. e20-e21
nvt p.
|
artikel
|
| 10 |
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study
|
De Nicolò, A.
|
|
2017
|
49 |
1S |
p. e61-
1 p.
|
artikel
|
| 11 |
Assessment of Sepsis-3 criteria in patients with cirrhosis and bacterial infections
|
Piano, S.
|
|
2017
|
49 |
1S |
p. e18-
1 p.
|
artikel
|
| 12 |
Autoimmune hepatitis in children and adults: A single centre experience
|
Perini, L.
|
|
2017
|
49 |
1S |
p. e24-
1 p.
|
artikel
|
| 13 |
Bacterial infection is an uncommon occurrence in cirrhotic patients undergoing endoscopic variceal ligation
|
Maimone, S.
|
|
2017
|
49 |
1S |
p. e57-
1 p.
|
artikel
|
| 14 |
CEUS LI-RADS are effective in predicting the risk hepatocellular carcinoma of liver nodules
|
Terzi, E.
|
|
2017
|
49 |
1S |
p. e22-
1 p.
|
artikel
|
| 15 |
Characterisation of the immune response in patients with drug induced liver injury
|
Bergamo, C.
|
|
2017
|
49 |
1S |
p. e15-
1 p.
|
artikel
|
| 16 |
Child-Pugh score predicts ribavirin overexposure in cirrhotic patients treated with direct-acting antiviral agents
|
Guardigni, V.
|
|
2017
|
49 |
1S |
p. e46-
1 p.
|
artikel
|
| 17 |
Cirrhosis regression does not prevent hepatocellular carcinoma in patients with a sustained virological response to IFN
|
D’Ambrosio, R.
|
|
2017
|
49 |
1S |
p. e33-e34
nvt p.
|
artikel
|
| 18 |
Clinical effectiveness of enhanced surveillance in “super-high risk” cirrhotics as evaluated in the ITA.LI.CA database
|
D’Elia, M.
|
|
2017
|
49 |
1S |
p. e31-
1 p.
|
artikel
|
| 19 |
Clinical outcomes with long-term sorafenib treatment: A multicenter, real-life study
|
Sacco, R.
|
|
2017
|
49 |
1S |
p. e38-
1 p.
|
artikel
|
| 20 |
Clinical presentation and outcomes of hepatocellular carcinoma in elderly patients referred to a tertiary center: 5-Years experience
|
Okolicsanyi, S.
|
|
2017
|
49 |
1S |
p. e23-
1 p.
|
artikel
|
| 21 |
Comparative antiviral efficacy with higher ALT normalization of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in HBeAg-negative, genotype D chronic hepatitis B
|
Ricco, G.
|
|
2017
|
49 |
1S |
p. e63-
1 p.
|
artikel
|
| 22 |
Copper levels contribute together with the myc oncogene to liver transformation
|
Porcu, C.
|
|
2017
|
49 |
1S |
p. e37-e38
nvt p.
|
artikel
|
| 23 |
DAA-based regimens in HBsAg/anti-HCV positive patients: The need to control HBV replication to avoid HBV reactivation
|
Macera, M.
|
|
2017
|
49 |
1S |
p. e34-e35
nvt p.
|
artikel
|
| 24 |
DAAs treatment in HCV recurrence after liver transplantation: Clinical usefulness of non-invasive methods
|
Ravaioli, F.
|
|
2017
|
49 |
1S |
p. e39-
1 p.
|
artikel
|
| 25 |
Daclatasvir/sofosbuvir and ribavirin 800mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience
|
Pellicelli, A.
|
|
2017
|
49 |
1S |
p. e64-
1 p.
|
artikel
|
| 26 |
Decreased alpha-fetoprotein levels in HCV cirrhotic patients after direct-acting antiviral agents therapy. Does this indicate a reduced risk of hepatocellular carcinoma?
|
De Leonardis, F.
|
|
2017
|
49 |
1S |
p. e56-
1 p.
|
artikel
|
| 27 |
Direct acting antiviral (DAA) therapy of HCV, effects on the cryoglobulinemic vasculitis: A multi center open label study
|
Mauro, E.
|
|
2017
|
49 |
1S |
p. e32-
1 p.
|
artikel
|
| 28 |
Down-regulation of hepatic MBOAT7 by hyperinsulinemia favors steatosis development
|
Meroni, M.
|
|
2017
|
49 |
1S |
p. e3-e4
nvt p.
|
artikel
|
| 29 |
Durable response in the markers of cholestasis through 24 months of open-label extension with obeticholic acid in Italian patients with primary biliary cholangitis
|
Andreone, P.
|
|
2017
|
49 |
1S |
p. e21-
1 p.
|
artikel
|
| 30 |
Dynamic risk prediction in Primary Biliary Cholangitis using the UK-PBC cohort
|
Carbone, M.
|
|
2017
|
49 |
1S |
p. e32-e33
nvt p.
|
artikel
|
| 31 |
Early changes in non invasive assessment of liver fibrosis in hepatitis C virus-infected patients treated with DAAs: Preliminary reports
|
Iegri, C.
|
|
2017
|
49 |
1S |
p. e69-
1 p.
|
artikel
|
| 32 |
Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs)
|
Calvaruso, V.
|
|
2017
|
49 |
1S |
p. e60-
1 p.
|
artikel
|
| 33 |
Editorial Board
|
|
|
2017
|
49 |
1S |
p. i-
1 p.
|
artikel
|
| 34 |
Effectiveness of HCV antiviral treatment in patients with cirrhosis or advanced fibrosis and end-stage kidney disease on dialysis
|
Ponziani, F.R.
|
|
2017
|
49 |
1S |
p. e24-e25
nvt p.
|
artikel
|
| 35 |
Effectiveness of percutaneous ethanol injection in relation to hepatocellular carcinoma size: A single centre experience
|
Di Costanzo, G.G.
|
|
2017
|
49 |
1S |
p. e44-
1 p.
|
artikel
|
| 36 |
Effect of interferon free antiviral therapy on glomerular and tubular kidney involvement in HCV child-A cirrhosis
|
Palazzo, D.
|
|
2017
|
49 |
1S |
p. e67-
1 p.
|
artikel
|
| 37 |
Effects of treatment with Maraviroc a CCR5 inhibitor on a human hepatic stellate cell line
|
Coppola, N.
|
|
2017
|
49 |
1S |
p. e46-
1 p.
|
artikel
|
| 38 |
Efficacy of early empiric antibiotic treatment and its impact on short-term mortality in cirrhotic patients with subsequent identification of the infecting bacteria
|
Caccamo, G.
|
|
2017
|
49 |
1S |
p. e58-
1 p.
|
artikel
|
| 39 |
Efficacy of oral direct acting antivirals for treatment of advanced chronic hepatitis or compensated cirrhosis due to hepatitis C virus infection: The real-life experience of the Sicily registry
|
Cacciola, I.
|
|
2017
|
49 |
1S |
p. e6-
1 p.
|
artikel
|
| 40 |
Emerging players in liver fibrosis regression in a chronic murine model of hepatic injury
|
Crescenzi, M.
|
|
2017
|
49 |
1S |
p. e64-
1 p.
|
artikel
|
| 41 |
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: A multicenter real-life study in 103 patients
|
Viganò, M.
|
|
2017
|
49 |
1S |
p. e37-
1 p.
|
artikel
|
| 42 |
Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal
|
Manini, M.A.
|
|
2017
|
49 |
1S |
p. e10-e11
nvt p.
|
artikel
|
| 43 |
Epidemiology of primary biliary cholangitis in Italy: evidences from a real world database
|
Marzioni, M.
|
|
2017
|
49 |
1S |
p. e14-
1 p.
|
artikel
|
| 44 |
Eradication of HCV in patients awaiting liver transplantation does not increase drop-out due to HCC progression
|
Shalaby, S.
|
|
2017
|
49 |
1S |
p. e47-
1 p.
|
artikel
|
| 45 |
Established cirrhosis at the time of diagnosis predicts adverse outcome in autoimmune hepatitis: A retrospective cohort study
|
Gerussi, A.
|
|
2017
|
49 |
1S |
p. e33-
1 p.
|
artikel
|
| 46 |
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in patients with chronic HCV infection treated with direct antiviral agents
|
Onali, S.
|
|
2017
|
49 |
1S |
p. e63-
1 p.
|
artikel
|
| 47 |
External validation of the HCC-MELD score for patients with hepatocellular carcinoma waiting for liver transplantation
|
Vitale, A.
|
|
2017
|
49 |
1S |
p. e10-
1 p.
|
artikel
|
| 48 |
External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study
|
Dionigi, E.
|
|
2017
|
49 |
1S |
p. e4-
1 p.
|
artikel
|
| 49 |
Extracellular vesicles induce renal tubular cells apoptosis, oxidative stress and functional abnormalities in patients with an acute decompensation of cirrhosis
|
Brocca, A.
|
|
2017
|
49 |
1S |
p. e17-
1 p.
|
artikel
|
| 50 |
FAK depletion/inhibition reduces the expression of liver cancer stem cells markers
|
Romito, I.
|
|
2017
|
49 |
1S |
p. e48-
1 p.
|
artikel
|
| 51 |
Frailty index is a strong predictor of in-hospital outcomes and mortality after discharge in cirrhotic patients
|
Caccamo, G.
|
|
2017
|
49 |
1S |
p. e57-
1 p.
|
artikel
|
| 52 |
Genetic variations in PD-1 and STAT4 genes do not predict off-treatment functional cure in IFN treated genotype D, HBeAg-negative patients with chronic hepatitis B
|
Galmozzi, E.
|
|
2017
|
49 |
1S |
p. e29-
1 p.
|
artikel
|
| 53 |
Genotype 3 infection in DAA era: Reports of a real life Northern Italy Network for viral hepatitis after 2 years by the start
|
Pasulo, L.
|
|
2017
|
49 |
1S |
p. e68-
1 p.
|
artikel
|
| 54 |
HBV reactivation in pOBI is influenced by detectable viremia at baseline rather than duration of prophylaxis with lamivudine
|
Cavallo, F.
|
|
2017
|
49 |
1S |
p. e59-
1 p.
|
artikel
|
| 55 |
HCC onset and features among chronic hepatitis B patients treated with nucleos(t)ide analogues
|
Schranz, M.
|
|
2017
|
49 |
1S |
p. e66-
1 p.
|
artikel
|
| 56 |
HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life
|
Cento, V.
|
|
2017
|
49 |
1S |
p. e53-
1 p.
|
artikel
|
| 57 |
Hepatocellular carcinoma and metabolic risk factors in a main reference center in Italy
|
Ibrahim Kamal Jouness, R.
|
|
2017
|
49 |
1S |
p. e36-
1 p.
|
artikel
|
| 58 |
Hepatocellular carcinoma recurrence rate in HCV infected patients treated with direct antiviral agents. A single center experience
|
Granata, R.
|
|
2017
|
49 |
1S |
p. e45-e46
nvt p.
|
artikel
|
| 59 |
High rate of misclassification of fibrosis stage using transient elastography thresholds to prioritize HCV patients for antiviral treatment
|
Calvaruso, V.
|
|
2017
|
49 |
1S |
p. e65-e66
nvt p.
|
artikel
|
| 60 |
High rates of renal tubular damage in HBV monoinfected patients long-term treated with tenofovir: A cross-sectional, single center, real-life study in 414 patients
|
Grossi, G.
|
|
2017
|
49 |
1S |
p. e9-
1 p.
|
artikel
|
| 61 |
HLA-G is highly expressed by plasma cells infiltrating hepatic tissue of patients affected by autoimmune hepatitis
|
Onali, S.
|
|
2017
|
49 |
1S |
p. e60-
1 p.
|
artikel
|
| 62 |
Hypoxia-inducible factor 2α drives the progression of experimental non-alcoholic fatty liver disease by stimulating hepatocyte production of histidine rich glycoprotein
|
Sutti, S.
|
|
2017
|
49 |
1S |
p. e27-
1 p.
|
artikel
|
| 63 |
Identification of Twinfilin-1 as a key regulator of cholangiocyte biological response to injury: Evidence for a possible role of ageing in the progression of cholangiopathies
|
Maroni, L.
|
|
2017
|
49 |
1S |
p. e13-
1 p.
|
artikel
|
| 64 |
Impact of Acute-on-Chronic Liver Failure (ACLF) on response to treatment with terlipressin and albumin in patients with type 1 hepatorenal syndrome
|
Piano, S.
|
|
2017
|
49 |
1S |
p. e54-
1 p.
|
artikel
|
| 65 |
Impact of adrenal dysfunction on psoas muscle thickness assessed by computed tomography in patients with liver cirrhosis
|
Privitera, G.
|
|
2017
|
49 |
1S |
p. e41-
1 p.
|
artikel
|
| 66 |
Impact of direct-acting anti-HCV treatments before liver transplant on virological and clinical outcomes of HCV patients at one year after surgery
|
Martini, S.
|
|
2017
|
49 |
1S |
p. e25-e26
nvt p.
|
artikel
|
| 67 |
Impact of multidisciplinary team approach to liver tumors: 5-Years experience
|
Okolicsanyi, S.
|
|
2017
|
49 |
1S |
p. e20-
1 p.
|
artikel
|
| 68 |
Impact of natural killer (NK) cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients
|
Onali, S.
|
|
2017
|
49 |
1S |
p. e5-
1 p.
|
artikel
|
| 69 |
Impact of von Willebrand factor and ADAMTS-13 on the pro-coagulant imbalance of patients with cirrhosis
|
La Mura, V.
|
|
2017
|
49 |
1S |
p. e34-
1 p.
|
artikel
|
| 70 |
Impairment of coronary microvascular function in patients with Primary Biliary Cholangitis
|
Cazzagon, N.
|
|
2017
|
49 |
1S |
p. e22-
1 p.
|
artikel
|
| 71 |
Increased hepatic glucose production and insulin resistance are associated to increased plasma concentrations of glucogenic amino acids in subjects with NAFLD
|
Gaggini, M.
|
|
2017
|
49 |
1S |
p. e1-
1 p.
|
artikel
|
| 72 |
Increase in transporter MATE-1 expression induced by obeticholic acid correlates with higher biliary excretion of asymmetric dimethylarginine during hepatic ischemia/reperfusion injury
|
Di Pasqua, L.G.
|
|
2017
|
49 |
1S |
p. e30-
1 p.
|
artikel
|
| 73 |
In experimental ascitic cirrhosis reduction of adrenergic function by means of α2A adrenergic receptor agonists has considerable aquaretic effects
|
Sansoè, G.
|
|
2017
|
49 |
1S |
p. e16-
1 p.
|
artikel
|
| 74 |
In experimental liver cirrhosis impaired secretion of renalase into blood may lead to organ damage and sympathetic overactivity
|
Sansoè, G.
|
|
2017
|
49 |
1S |
p. e20-
1 p.
|
artikel
|
| 75 |
In HBeAg-negative chronic HBV infection, HBsAg levels profoundly differ among HBV-genotypes and can be affected by the extent of HBsAg variability: Can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?
|
Salpini, R.
|
|
2017
|
49 |
1S |
p. e45-
1 p.
|
artikel
|
| 76 |
In HCV infected patients with cirrhosis Squamous Cell Carcinoma Antigen (SCCA)-IgM levels may contribute to identify the individual risk of HCC development after antiviral therapy
|
Ricco, G.
|
|
2017
|
49 |
1S |
p. e48-e49
nvt p.
|
artikel
|
| 77 |
Inherited prothrombotic risk factors in children with extrahepatic portal vein obstruction(EHPVO). A case–control study
|
Primignani, M.
|
|
2017
|
49 |
1S |
p. e30-
1 p.
|
artikel
|
| 78 |
In-hospital mortality and length of stay in cirrhotic patients with sepsis treated with non-selective beta-blockers
|
Facciorusso, A.
|
|
2017
|
49 |
1S |
p. e15-
1 p.
|
artikel
|
| 79 |
Laparoscopic ablation for HCC: proposal of a 6-months mortality score for patient selection based on more than 1000 procedures
|
Bertacco, A.
|
|
2017
|
49 |
1S |
p. e51-
1 p.
|
artikel
|
| 80 |
Liver microRNA hsa-miR-125a-5p may exert an oncosuppressor effect on HCC
|
Onorato, L.
|
|
2017
|
49 |
1S |
p. e35-
1 p.
|
artikel
|
| 81 |
Liver stiffness and portal hypertension predict failure to DAA treatment in a real-life cohort of HCV-infected patients treated with recommended regimens
|
Masetti, C.
|
|
2017
|
49 |
1S |
p. e50-e51
nvt p.
|
artikel
|
| 82 |
Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients
|
Ravaioli, F.
|
|
2017
|
49 |
1S |
p. e39-
1 p.
|
artikel
|
| 83 |
Liver Stiffness Based Model (LSPS) predicts portal hypertension (PH), esofageal varices (EV) and HCC in Caucasian patients with HBV-related cirrhisis responsive to antiviral therapy
|
Tucci, A.
|
|
2017
|
49 |
1S |
p. e58-
1 p.
|
artikel
|
| 84 |
Liver stiffness fibrosis thresholds of Fibroscan cannot be adopted by all new elastography machines: A comparative study
|
Salvatore, V.
|
|
2017
|
49 |
1S |
p. e24-
1 p.
|
artikel
|
| 85 |
Lobe-specific oxidative stress and matrix metalloproteinase activation in two animal models of non-alcoholic fatty liver disease (NAFLD)
|
Siciliano, V.
|
|
2017
|
49 |
1S |
p. e31-
1 p.
|
artikel
|
| 86 |
Local prothrombotic state in portal venous system in cirrhosis
|
Shalaby, S.
|
|
2017
|
49 |
1S |
p. e16-
1 p.
|
artikel
|
| 87 |
Local renin–angiotensin system in the kidney of ascitic cirrhosis: An innocent bystander or a major protagonist?
|
Sansoè, G.
|
|
2017
|
49 |
1S |
p. e21-
1 p.
|
artikel
|
| 88 |
Low viremic HBeAg negative HBsAg carriers: Clinical outcome and non invasive diagnostic accuracy for chronic hepatitis B or inactive infection by combinations of HBV markers
|
Oliveri, F.
|
|
2017
|
49 |
1S |
p. e54-e55
nvt p.
|
artikel
|
| 89 |
Metformin reduces cell migration and down-regulates epithelial to mesenchymal transition (EMT) by AMPK/Foxo3a pathway in human intrahepatic cholangiocarcinoma (CCA)
|
Di Matteo, S.
|
|
2017
|
49 |
1S |
p. e13-
1 p.
|
artikel
|
| 90 |
Microgravity maintains stemness and enhance glycolytic metabolism in human hepatic and biliary tree stem/progenitor cells
|
Costantini, D.
|
|
2017
|
49 |
1S |
p. e14-
1 p.
|
artikel
|
| 91 |
Minimal increases of alpha-fetoprotein strongly predict HCC development in caucasian compensated HBV cirrhotics treated by entecavir or tenofovir: A 7-year longitudinal cohort study in 225 patients
|
Loglio, A.
|
|
2017
|
49 |
1S |
p. e28-
1 p.
|
artikel
|
| 92 |
MiR-122 targets SerpinB3 and is involved in Sorafenib resistance in hepatocellular carcinoma
|
Pollutri, D.
|
|
2017
|
49 |
1S |
p. e28-
1 p.
|
artikel
|
| 93 |
Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies
|
Di Maio, V.C.
|
|
2017
|
49 |
1S |
p. e49-e50
nvt p.
|
artikel
|
| 94 |
Natural HCV resistance is common in Italy and differently associated to genotypes
|
Sorbo, M.C.
|
|
2017
|
49 |
1S |
p. e52-
1 p.
|
artikel
|
| 95 |
Non-invasive tools to ruling out large varices: RESIST-HCV vs Baveno VI criteria in a large cohort of patients with HCV cirrhosis
|
Calvaruso, V.
|
|
2017
|
49 |
1S |
p. e17-
1 p.
|
artikel
|
| 96 |
Oncostatin M induces increased invasiveness and angiogenesis in hepatic cancer cells through HIF1α-related release of VEGF-A
|
Foglia, B.
|
|
2017
|
49 |
1S |
p. e5-
1 p.
|
artikel
|
| 97 |
Outcome of liver transplant recipients after the first episode of bacterial infection
|
Ferrarese, A.
|
|
2017
|
49 |
1S |
p. e12-
1 p.
|
artikel
|
| 98 |
Parenchymal sparing vs. anatomic resection for hcc: A propensity score analysis
|
Famularo, S.
|
|
2017
|
49 |
1S |
p. e11-e12
nvt p.
|
artikel
|
| 99 |
Peripheral and intrahepatic virological phenotyping in HBeAg negative Chronic Hepatitis B to evaluate risk of disease progression and HCC in the “grey-zone” viral load cohort: Can grey-zone patients be candidate to treatment?
|
Salpini, R.
|
|
2017
|
49 |
1S |
p. e7-
1 p.
|
artikel
|
| 100 |
Platelet count, spleen length and platelet count/spleen length ratio for the diagnosis of oesophageal varices in patients with hepatic cirrhosis. A systematic review and meta-analysis
|
Colli, A.
|
|
2017
|
49 |
1S |
p. e22-e23
nvt p.
|
artikel
|
| 101 |
Portosystemic shunts in cirrhosis are associated to more complications and deteriorated quality of life. An international cohort study
|
Simón-Talero, M.
|
|
2017
|
49 |
1S |
p. e65-
1 p.
|
artikel
|
| 102 |
Pre-emptive post-liver transplant (LT) HCV treatment with DAAs: Proof of concept from a pilot study
|
Pasulo, L.
|
|
2017
|
49 |
1S |
p. e69-
1 p.
|
artikel
|
| 103 |
Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy
|
Di Maio, V.C.
|
|
2017
|
49 |
1S |
p. e62-e63
nvt p.
|
artikel
|
| 104 |
Prognostic role of vascular endothelial growth factor and hypoxia inducible factor in HCC patients after conventional and DEB-mediated chemoembolization
|
Meneghetti, A.
|
|
2017
|
49 |
1S |
p. e35-
1 p.
|
artikel
|
| 105 |
Prothrombotic microparticles and risk of portal vein thrombosis in patients with HCV-related liver cirrhosis who underwent DAA antiviral therapy
|
Zanetto, A.
|
|
2017
|
49 |
1S |
p. e9-
1 p.
|
artikel
|
| 106 |
Risk factors of early emergent hospital readmission and 6-month mortality in patients with cirrhosis after a recovery from bacterial or fungal infection
|
Morando, F.
|
|
2017
|
49 |
1S |
p. e44-
1 p.
|
artikel
|
| 107 |
Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs)
|
Cabibbo, G.
|
|
2017
|
49 |
1S |
p. e59-
1 p.
|
artikel
|
| 108 |
Role of SerpinB3 in the stimulation of macrophage activation marker sCD163 in HCV infected patients
|
Martini, A.
|
|
2017
|
49 |
1S |
p. e6-
1 p.
|
artikel
|
| 109 |
Ruling-in and ruling-out significant fibrosis and cirrhosis using a shear wave measurement method
|
Ferraioli, G.
|
|
2017
|
49 |
1S |
p. e23-
1 p.
|
artikel
|
| 110 |
Screening of oesophagogastric varices in virus-related compensated advanced chronic liver disease: Beyond the Baveno VI criteria
|
Tosetti, G.
|
|
2017
|
49 |
1S |
p. e38-
1 p.
|
artikel
|
| 111 |
Serial combination of noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with nonalcoholic fatty liver disease
|
Petta, S.
|
|
2017
|
49 |
1S |
p. e2-
1 p.
|
artikel
|
| 112 |
Serum markers for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment
|
Sangiovanni, A.
|
|
2017
|
49 |
1S |
p. e47-
1 p.
|
artikel
|
| 113 |
Spleen stiffness measurement: A useful prognostic tool in HCV patients treated with DAAs regimens
|
Ravaioli, F.
|
|
2017
|
49 |
1S |
p. e40-e41
nvt p.
|
artikel
|
| 114 |
Steatohepatitis and type 2 diabetes mellitus are influenced by genetic susceptibility to increased intestinal permeability in patients with non-alcoholic fatty liver disease
|
Giorgio, V.
|
|
2017
|
49 |
1S |
p. e3-
1 p.
|
artikel
|
| 115 |
Survival and recurrences after curative treatments of HCV-related early hepatocellular carcinoma. A meta-analysis of single arm studies
|
Cabibbo, G.
|
|
2017
|
49 |
1S |
p. e61-
1 p.
|
artikel
|
| 116 |
TERT promoter and CTNNB1 gene mutations represent cancer signatures specific for hepatitis B and hepatitis C related hepatocellular carcinoma
|
Pezzuto, F.
|
|
2017
|
49 |
1S |
p. e27-
1 p.
|
artikel
|
| 117 |
The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network
|
Cento, V.
|
|
2017
|
49 |
1S |
p. e8-
1 p.
|
artikel
|
| 118 |
The combination of mucus-degrading gram-negative bacteria and reduced antimicrobial peptides drives adipose tissue inflammation and NAFLD progression in mice lacking NLRP3-inflammasome
|
Pierantonelli, I.
|
|
2017
|
49 |
1S |
p. e2-e3
nvt p.
|
artikel
|
| 119 |
The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicentre cohort study
|
Vitale, A.
|
|
2017
|
49 |
1S |
p. e4-e5
nvt p.
|
artikel
|
| 120 |
The hepatic expression of lysosomal acid lipase (LAL) is reduced in NAFLD patients, and associated with features of genetically determined LAL deficiency and NAFLD activity score
|
Vespasiani-Gentilucci, U.
|
|
2017
|
49 |
1S |
p. e1-e2
nvt p.
|
artikel
|
| 121 |
The immunomodulatory activity of SerpinB3 an protease-inhibitor in vivo and in vitro
|
Cappon, A.
|
|
2017
|
49 |
1S |
p. e26-
1 p.
|
artikel
|
| 122 |
The old patient in DAA era: Real life reports on 5925 patients from the Lombardy HCV Network
|
Pasulo, L.
|
|
2017
|
49 |
1S |
p. e67-e68
nvt p.
|
artikel
|
| 123 |
The prevalence of liver diseases due Hepatitis C Virus (HCV) in Sicily: A population-based survey
|
Cartabellotta, F.
|
|
2017
|
49 |
1S |
p. e66-
1 p.
|
artikel
|
| 124 |
The role of Spleen Stiffness measurement as predictor of HCC recurrence after curative resection in cirrhotic patients
|
Marasco, G.
|
|
2017
|
49 |
1S |
p. e41-
1 p.
|
artikel
|
| 125 |
The survival benefit of laparoscopic ablation over trans-arterial chemoembolization in patients with hepatocellular carcinoma ineligible for liver resection or percutaneous ablation
|
Bertacco, A.
|
|
2017
|
49 |
1S |
p. e12-
1 p.
|
artikel
|
| 126 |
Thromboelastographic evaluation of hemostatic balance in cirrhotic patients with infection
|
Nadal, E.
|
|
2017
|
49 |
1S |
p. e55-
1 p.
|
artikel
|
| 127 |
Transjugular intrahepatic portosystemic shunt is a safe and effective approach in cirrhotic patients with splanchnic vein thrombosis
|
Airoldi, A.
|
|
2017
|
49 |
1S |
p. e56-
1 p.
|
artikel
|
| 128 |
Treatment of chronic hepatitis C in Lombardia: An analysis on the safety and efficacy of DAA therapy in 5457 patients
|
Aghemo, A.
|
|
2017
|
49 |
1S |
p. e70-
1 p.
|
artikel
|
| 129 |
Treatment with direct-acting antiviral agents is associated with improvement of renal function in a cohort of HCV-infected patients with chronic kidney disease
|
Masetti, C.
|
|
2017
|
49 |
1S |
p. e51-
1 p.
|
artikel
|
| 130 |
Ultrasound-guided Percutaneous Irreversible Electroporation (IRE) of Hepatocellular Carcinoma (HCC) not suitable for surgery or thermal ablation: Initial report on safety and efficacy from a western center
|
Giorgio, A.
|
|
2017
|
49 |
1S |
p. e55-e56
nvt p.
|
artikel
|
| 131 |
Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma
|
Tortora, R.
|
|
2017
|
49 |
1S |
p. e42-
1 p.
|
artikel
|
| 132 |
Validation of Liver Imaging Reporting and Data System (LI-RADS) Version 2014
|
Pecorelli, A.
|
|
2017
|
49 |
1S |
p. e49-
1 p.
|
artikel
|
| 133 |
Validation of the Baveno VI criteria for screening of esophageal varices in patients with metabolic and alcohol related compensated advanced chronic liver disease
|
Mezzina, N.
|
|
2017
|
49 |
1S |
p. e29-
1 p.
|
artikel
|
| 134 |
Validation of the Bolondi stratification for intermediate stage hepatocellular carcinoma (HCC). Clinical and therapeutical implications
|
Mega, A.
|
|
2017
|
49 |
1S |
p. e25-
1 p.
|
artikel
|
| 135 |
Vitamin D deficiency is an independent risk factor and is predictor of infections in patients affected by HCV-related liver cirrhosis
|
Buonomo, A.R.
|
|
2017
|
49 |
1S |
p. e31-e32
nvt p.
|
artikel
|
| 136 |
Worsening of serum lipid profile after direct acting antiviral treatment
|
Gitto, S.
|
|
2017
|
49 |
1S |
p. e26-
1 p.
|
artikel
|
Tijdschrift beschrijving